Expertise in
5
conditions

Dr. Ari M. Vanderwalde

Oncology
St. Jude Children's Research Hospital
262 Danny Thomas Pl, 
Memphis, TN 
Accepting New Patients
Offers Telehealth
Expertise in
5
conditions
St. Jude Children's Research Hospital
262 Danny Thomas Pl, 
Memphis, TN 

Overview

Ari Vanderwalde is an Oncologist practicing medicine in Memphis, Tennessee.

Dr. Vanderwalde is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Melanoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Olfactory Neuroblastoma.

He is actively involved in clinical research, co-authoring 75 peer reviewed articles and participating in 6 clinical trials. Dr. Vanderwalde is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

St. Jude Children's Research Hospital
262 Danny Thomas Pl, Memphis, TN 38105
Other Locations
The West Clinic PLLC
7945 Wolf River Blvd, Germantown, TN 38138

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2026
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2026
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
View 4 Less Clinical Trials

75 Total Publications

The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression.
The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression.
Journal: Cancer medicine
Published: April 20, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Amar J. Gajjar
Hematology | Oncology
Expertise in
17
conditions
Dr. Amar J. Gajjar
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-2615
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amar Gajjar is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Gajjar is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Posterior Fossa Tumor, Brain Tumor, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Decompression. Dr. Gajjar is currently accepting new patients.

Expertise in
13
conditions
Dr. Giles W. Robinson
Hematology | Oncology
Expertise in
13
conditions
Dr. Giles W. Robinson
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-5175
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Giles Robinson is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Robinson is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, and Rhabdoid Tumor. Dr. Robinson is currently accepting new patients.

Expertise in
8
conditions
Dr. Jane S. Hankins
Hematology | Oncology
Expertise in
8
conditions
Dr. Jane S. Hankins
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-4153
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jane Hankins is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Hankins is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Adenoidectomy. Dr. Hankins is currently accepting new patients.

Frequently Asked Questions about Dr. Ari M. Vanderwalde

How do I make an appointment with Dr. Ari M. Vanderwalde?

You can book an appointment with Dr. Ari M. Vanderwalde by calling their office at 888-226-4343. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ari M. Vanderwalde a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ari M. Vanderwalde is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ari M. Vanderwalde specialize in?

While Dr. Ari M. Vanderwalde is a Oncology, they have specific expertise in Melanoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Ari M. Vanderwalde participate in research or clinical trials?

Yes. Dr. Ari M. Vanderwalde has published 75 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Ari M. Vanderwalde's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ari M. Vanderwalde accept my insurance?

Dr. Ari M. Vanderwalde accepts most major insurance plans, including Cigna and Humana. We recommend calling the office directly at 888-226-4343 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vanderwalde's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile